Document is current
Any future updates will be listed below
-
Authors
D’Agostino, Mattia https://orcid.org/0000-0002-1711-6996
Martello, Marina https://orcid.org/0000-0001-8196-8707
De Paoli, Lorenzo https://orcid.org/0000-0002-7488-8247
Mangiacavalli, Silvia https://orcid.org/0000-0001-9787-3083
Derudas, Daniele https://orcid.org/0000-0002-0997-4157
Fazio, Francesca https://orcid.org/0000-0003-4187-8912
Furlan, Anna https://orcid.org/0000-0001-6443-3241
Liberatore, Carmine https://orcid.org/0000-0003-0948-9343
Mele, Giuseppe https://orcid.org/0000-0003-4813-8618
Mina, Roberto https://orcid.org/0000-0002-8144-541X
Ria, Roberto https://orcid.org/0000-0002-1515-0090
Zamagni, Elena https://orcid.org/0000-0003-1422-7305
-
Funding
Funding for this research was provided by:
Alma Mater Studiorum - Università di Bologna
- License Information
-
More Information
Article History
Received: 4 October 2024
Accepted: 13 January 2025
First Online: 13 February 2025
Declarations
:
: Mattia D’Agostino has received honoraria for lectures from GSK, Sanofi and Janssen; and has served on the advisory boards of GSK, Sanofi and Bristol Myers Squibb/Celgene. Marina Martello has received honoraria from Takeda, Bristol Myers Squibb/Celgene, Sanofi, Janssen and GSK. Lorenzo De Paoli has received honoraria from Janssen, Sanofi, GSK, Menarini, Amgen, AstraZeneca, BeiGene and AbbVie; and has served on the advisory boards of GSK, Menarini, Amgen and Janssen. Silvia Mangiacavalli has received honoraria from Janssen, Sanofi, GSK, Menarini and Pfizer; has served on the advisory boards of Janssen, Sanofi, Bristol Myers Squibb/Celgene, GSK, Menarini and Takeda; and has received consultancy fees from Janssen. Daniele Derudas has received speaker fees from GSK, Johnson & Johnson, Bristol Myers Squibb/Celgene, Takeda and Amgen. Francesca Fazio has received honoraria from Janssen and GSK; has served on the advisory boards of GSK; and has received consultancy fees from Janssen, Menarini and Amgen. Anna Furlan has served on the advisory boards of Janssen, Takeda, Menarini, Amgen, Sanofi and GSK; and has received honoraria from Janssen, Takeda, Sanofi, GSK and Bristol Myers Squibb/Celgene. Carmine Liberatore has received honoraria from Janssen, Sanofi, GSK and Menarini; has served on advisory boards for Janssen, Sanofi, Bristol Myers Squibb/Celgene, GSK, Amgen, Menarini and Takeda; and received consultancy fees from GSK. Giuseppe Mele has received honoraria from Janssen, Sanofi, Amgen, Menarini, Celgene and Takeda; and has served on advisory boards for Janssen, Amgen, Menarini and Bristol Myers Squibb/Celgene. Roberto Mina has received honoraria from Janssen, Celgene, Takeda and Amgen; served on the advisory boards of Janssen, Takeda, Bristol Myers Squibb/Celgene, Amgen and Pfizer; and has received consultancy fees from Janssen, Takeda and Sanofi. Roberto Ria has served on the speaker’s bureau of Amgen, Bristol Myers Squibb/Celgene, CSL Behring, Janssen Cilag, Octapharma and Takeda; and was a consultant for Amgen, Bristol Myers Squibb/Celgene, CSL Behring, GSK, Janssen Cilag, Pfizer, Sanofi and Takeda. Elena Zamagni has received honoraria from and has served in an advisory role for Janssen, Bristol-Myers Squibb/Celgene, Sanofi, Amgen, GSK, Pfizer, Oncopeptides and Menarini-Stemline.
